What Role Does Balloon Angioplasty Play in Modern Cardiac Care?
Percutaneous Coronary Intervention (PCI) Devices Market
Valued at USD 9.50 billion in the 2024 base year, the percutaneous coronary intervention (PCI) devices market is projected to reach USD 10.02 billion in 2025 and USD 16.47 billion by 2034, growing at a CAGR of 5.68% during the forecast period 2025–2034. Innovation in robotic-assisted PCI, catheter technologies, and imaging is intensifying competition. Leading companies include Abbott, Boston Scientific Corporation, Medtronic PLC, Terumo Corporation, ASAHI INTECC Company Limited, Cordis, Merit Medical System, B. Braun, BIOTRONIK, and Meril Lifesciences.
Robotic-Assisted PCI Emerges as a Key Trend
Robotic-assisted PCI (R-PCI), in which robots perform interventions remotely, is expected to become a key industry trend. Systems comprise a cockpit and a robotic arm, and benefits include reduced radiation exposure, enhanced ergonomics, improved precision, and potential for tele-stenting. Rising integration of AI, machine learning, and advanced imaging is expected to boost development, although high costs and technology constraints hinder adoption. Corindus (Siemens Healthineers) offers the CorPath GRX platform with U.S. FDA approval, Robocath develops its Robotic Angioplasty System, Corindus is running clinical studies on long-term outcomes while integrating advanced imaging for improved guidance, and Stereotaxis provides the Niobe ES magnetic navigation system. Medtronic is developing specialized tools for cardiac interventions, Intuitive Surgical is exploring cardiac applications for its da Vinci system, and Philips Healthcare pairs Azurion with FlexArm imaging and AI-driven analytics. Robocath is expanding internationally and collaborating with healthcare organizations on real-world data collection, and Auris Health (Johnson & Johnson) is integrating AI and machine learning on its Monarch platform while partnering with academic institutions.
Coronary Catheters and Guidewires Complete the Toolkit
The PCI devices market is segmented into coronary catheters, coronary guidewires, stents, and accessories. Improved balloon technologies and advanced catheters are propelling competition, and companies are investing in product innovation to broaden their reach. Competition stems from a rise in cardiovascular cases and healthcare systems emphasizing minimally invasive treatments. Continuing improvements in imaging and navigation tools further influence the landscape. ASAHI INTECC Company Limited, Terumo Corporation, Merit Medical System, Cook, and Cordis are among the key players profiled, alongside diversified medical technology leaders such as Abbott, Medtronic PLC, and Boston Scientific Corporation.
Balloon Angioplasty Volumes and Disease Burden
Physicians in the U.S. perform approximately 300,000 balloon angioplasty procedures annually, and the CDC states that someone in the country suffers a heart attack every 40 seconds. About 2.4 million Canadians aged 20 and above live with ischemic heart disease, and every 7 minutes cardiovascular disease kills one person in Canada. In the European region, the disease burden of cardiovascular disease exceeds that of AIDS, tuberculosis, and malaria combined. Diabetes, obesity, and sedentary lifestyles add to the risk, increasing PCI procedures and supporting the percutaneous coronary intervention (PCI) devices market. Globalization, urbanization, alcohol, tobacco, and inactivity also contribute to the growing number of heart disease cases.
Catheterization Labs and End-Use Dynamics
By end use, the market spans hospitals, ambulatory surgical centers, and catheterization labs. Hospitals held the largest share in 2024 owing to higher patient admissions advanced diagnostic and therapeutic systems, trained professionals, and advanced robotic devices performing PCI techniques, and the Affordable Care Act's pressure to reduce costs increases hospital utilization. Ambulatory surgical centers and catheterization labs complete the end-use segmentation. Geographically, North America was the largest revenue contributor in 2024, while Asia Pacific is projected to grow at the fastest rate owing to technological advancements.
Challenges and Outlook for the Percutaneous Coronary Intervention (PCI) Devices Market
Procedure-related challenges include allergies to local anesthesia, adverse reactions to contrast media, and complications during cardiac catheterization such as bleeding, infection, and pain at the insertion site, and a catheter may puncture a blood vessel. The high cost of devices may also hamper growth. Nevertheless, strong competition, rising cardiovascular cases, and healthcare emphasis on minimally invasive treatment are expected to keep the market dynamic.
More Trending Latest Reports By Polaris Market Research:
outsourced-semiconductor-assembly-and-test-market
global-paints-and-coatings-market
multiparameter-patient-monitoring-market
Comments
0 comment